Madrigal reports ‘positive’ results from Phase 3 MAESTRO-NAFLD-1 trial
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS
Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...
Madrigal Pharma stock jumps on positive trial results and revenue beat
Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Zacks.com on MSN7h
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...
pharmaphorum4d
Madrigal sees road to approval for NASH drug resmetirom
Earlier this year, Madrigal reported positive results in another phase 3 trial of resmetirom called MAESTRO-NAFLD-1, including some patients with NASH, and said a filing in the lead indication of ...
pharmaphorum3d
Madrigal Pharma is first over the MASH finish line
The FDA’s accelerated approval is based mainly on two phase 3 trials, MAESTRO-NASH and MAESTRO-NAFLD-1, which showed that a higher proportion of patients treated with Rezdiffra achieved NASH ...
BioSpace22d
Non-alcoholic fatty liver disease (NAFLD) Market to Reach USD 19.1 Million by 2035, Impelled by Advancements in Diagnostic Techniques
Looking forward, IMARC Group expects the 7MM to reach USD 19.1 Million by 2035, exhibiting a growth rate (CAGR) of 3 ... NAFLD market toward sustained growth. · In January 2024, Sagimet Biosciences ...
Frontiers24d
Fatty infiltration of the pancreas: a systematic concept analysis
The liver produces CRP, an acute-phase protein ... hyperlipidemia, and fatty liver, each of which is assigned a score of 1, resulting in a maximum score of 3. The scoring system has demonstrated high ...